201P Phase II study of taminadenant (A2AR antagonist) + spartalizumab (anti PD-1 antibody) in patients with triple-negative breast cancer (TNBC)
- Resource Type
- Abstract
- Authors
- Jerusalem, G.; De Braud, F.G.M.; de Jonge, M.J.A.; Grell, P.; Gonçalves, A.; Tan, T.J.Y.; Greil, R.; Yap, T.A.; Lin, C-C.; Kornbluth, K.A.; Yang, X.; Vong, C.; Choudhury, S.; Mataraza, J.; Lee, L.H.; Otero, J.A.; Garralda, E.
- Source
- In Immuno-Oncology and Technology December 2022 16 Supplement 1
- Subject
- Language
- ISSN
- 2590-0188